Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Glecirasib (JAB-21822) in Healthy Subjects
NCT06162169Phase 1Completed
- Sponsor
- Allist Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of glecirasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC) and 1 more (4 arms), sponsored by Allist Pharmaceuticals. Primary endpoints: Observed maximum concentrations (Cmax) of JAB-21822 at 10 days, Area under the concentration versus time curve from dose to the last quantifiable concentration (AUC0-t) of JAB-21822 at 10 days and 4 more. Started Nov 2023; status: completed.
02
Drugs
glecirasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT06162169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06162169.